Clinical Trial Update: Temsirolimus With or Without Megestrol Acetate and Tamoxifen Citrate in Treating Patients With Advanced, Persistent, or Recurrent Endometrial Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating temsirolimus with or without megestrol acetate and tamoxifen citrate in patients with advanced, persistent, or recurrent endometrial …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Cancer
• Uterine Corpus Cancer

Drugs mentioned

• Tamoxifen citrate (tamoxifen citrate)
• Temsirolimus (temsirolimus)
• megastrol acetate (megestrol acetate)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Endometrial Carcinoma, Recurrent Uterine Corpus Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2018-08-27